公开(公告)号：US20240123046A1

公开(公告)日：2024-04-18

申请号：US18257814

申请日：2021-12-17

申请人： THE SCRIPPS RESEARCH INSTITUTE ,  FRED HUTCHINSON CANCER RESEARCH CENTER

发明人： William R. SCHIEF ,  Kristen COHEN ,  Julie MCELRATH

IPC分类号： A61K39/02 ,  C07K14/005 ,  C07K14/74 ,  C12N9/10

CPC分类号： A61K39/0208 ,  C07K14/005 ,  C07K14/70539 ,  C12N9/1085 ,  A61K2039/53 ,  C12Y205/01078

摘要： Provided herein are compositions comprising novel MHC class II T cell epitopes and method using thereof. In some embodiments, a composition described herein comprises an immunogenic polypeptide comprising an MHC class II T cell epitope and a target antigen. In some embodiments, the target antigen is a viral, bacterial, parasite or tumor specific antigen. In some embodiments, the target antigen comprises a virus, bacteria, parasite or tumor specific polypeptide. In some embodiments, the composition comprises a fusion polypeptide comprising the immunogenic polypeptide and the target polypeptide. Also provided are polynucleotides encoding the fusion polypeptide, and methods of administering a composition comprising the polynucleotide to a subject to elicit an immune response. In some embodiments, the polynucleotide is an RNA comprising modified ribonucleotides.

公开(公告)号：US20240011067A1

公开(公告)日：2024-01-11

申请号：US18254531

申请日：2021-11-30

申请人： Universiteit Antwerpen

发明人： Sarah LEBEER ,  Sarah AHANNACH ,  Irina SPACOVA ,  Stijn WITTOUCK

IPC分类号： C12P25/00 ,  C12N9/78 ,  C12N9/04 ,  C12N9/10 ,  C12N9/88 ,  C12N9/12

CPC分类号： C12P25/00 ,  C12N9/78 ,  C12Y305/04026 ,  C12N9/0006 ,  C12Y101/01193 ,  C12N9/1085 ,  C12Y205/01009 ,  C12Y205/01078 ,  C12N9/88 ,  C12Y401/99012 ,  C12N9/1241 ,  C12Y207/07002 ,  C12N9/1205 ,  C12Y207/01026

摘要： The present invention to the identification of a novel isolated bacterial strain, the Limosilactobacillus reuteri strain which is characterized by a naturally occurring overproduction of riboflavin (vitamin B2) compared to other known strains of lactobacilli. Said strain of the Limosilactobacillus species is deposited under accession number LMG P-32020. In a further aspect, also the uses of said L. reuteri strain are disclosed herein. In particular, the use of said strain in food and feed industry, human and veterinary health, large-scale vitamin production, cosmetics and consumer care products is disclosed.

公开(公告)号：US20240076356A1

公开(公告)日：2024-03-07

申请号：US18268105

申请日：2021-12-20

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Mark M. Davis ,  Venkata Vamsee Aditya Mallajosyula

IPC分类号： C07K14/79 ,  C07K14/74 ,  C12N9/10 ,  G01N33/569

CPC分类号： C07K14/79 ,  C07K14/70539 ,  C12N9/1085 ,  G01N33/56972 ,  C07K2319/90 ,  C12Y205/01078

摘要： An antigen-specific T cell binding agent is provided, where a multivalent ‘spheromer’ system utilizes a scaffold of a self-assembling polypeptide nanoparticle, for example using selfassembling ferritin polypeptides. The system is compatible with current pMHC reagents, including both MHC-I and MHC-II molecules, and streptavidin reagents that allow ease-of-use. The spheromer assembly pipeline provides a consistent reagent across multiple batches of synthesis with ease of production. The defined geometry of the scaffold allows precise site-directed conjugation of pMHC, leading to a homogenous reagent. The spheromer binds cognate TCRs with a significantly higher avidity than a tetrameric reagent.

公开(公告)号：US20160115459A1

公开(公告)日：2016-04-28

申请号：US14894484

申请日：2014-05-26

申请人： Martín Diego Linus SPATZ ,  INMUNOVA S.A.

发明人： Fernando Alberto GOLDBAUM ,  Vanesa ZYLBERMAN ,  Patricio Oliver CRAIG ,  Giselle GHERSI ,  Marina Sandra PALERMO ,  Maria Pilar MEJIAS ,  Leticia Veronica BENTANCOR

IPC分类号： C12N9/10 ,  C07K16/12 ,  A61K38/45 ,  C07K16/40 ,  C07K14/245 ,  A61K39/108

CPC分类号： C12N9/1085 ,  A61K38/00 ,  A61K38/45 ,  A61K39/0258 ,  A61K39/098 ,  A61K2039/505 ,  A61K2039/523 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/6068 ,  C07K14/245 ,  C07K16/1232 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/20 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2319/55 ,  C12Y205/01078 ,  Y02A50/474

摘要： Chimeric polypeptides useful as immunogens for inducing protective immune responses and neutralizing antibodies against Shiga toxin (Stx) in mammals. More specifically, chimeric polypeptides having a monomer of the homopentameric B subunit of the Shiga 2 toxin fused to the N-terminus of a monomer of Brucella lumazine synthase, and to oligomeric protein complexes formed from said chimeric polypeptides. Polynucleotides and vectors encoding said chimeric polypeptides, transgenic cells having said polynucleotides and vectors, pharmaceutical compositions, such as a vaccine, having said chimeric polypeptides and chimeric polynucleotides, antibodies which bind to the chimeric polypeptides, a method for obtaining antibodies which bind specifically to the subunit B of the Shiga 2 toxin and methods of lowering the bacterial load of enterohemorrhagic Escherichia coli in mammals, which can be used for prevention of inter cilia, hemolytic-ureic syndrome (HUS), are also provided.

摘要翻译： 嵌合多肽可用作诱导保护性免疫应答的免疫原并中和哺乳动物志贺毒素（Stx）的抗体。 更具体地，具有与Brucella lumazine合酶的单体的N末端融合的志贺二毒素的同基因聚合物B亚基的单体的嵌合多肽和由所述嵌合多肽形成的寡聚蛋白复合物。 编码所述嵌合多肽的多核苷酸和载体，具有所述多核苷酸和载体的转基因细胞，具有所述嵌合多肽和嵌合多核苷酸的药物组合物，例如疫苗，与嵌合多肽结合的抗体，获得与 也提供了滋贺2毒素的亚基B和降低哺乳动物肠出血性大肠杆菌的细菌负荷的方法，其可用于预防纤维蛋白溶解性尿毒症综合征（HUS）。

公开(公告)号：US12053520B2

公开(公告)日：2024-08-06

申请号：US17587817

申请日：2022-01-28

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Xuejun Chen ,  Jeffrey Boyington ,  Hongying Duan Holdsworth ,  Cheng Cheng ,  John R. Mascola

IPC分类号： A61K39/21 ,  C07K14/005 ,  C07K14/16 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/21 ,  C07K14/005 ,  C07K14/162 ,  C12N7/00 ,  C12Y205/01078 ,  A61K2039/5258 ,  A61K2039/55555 ,  C07K2319/00 ,  C12N2740/16023 ,  C12N2740/16043 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171

摘要： Embodiments of immunogens based on the outer domain of HIV-1 gp120 and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to prime an immune response to gp120 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

公开(公告)号：US20180194809A1

公开(公告)日：2018-07-12

申请号：US15844753

申请日：2017-12-18

申请人： International AIDS Vaccine Initiative ,  The Scripps Research Institute

发明人： William Schief ,  Sergey Menis ,  Daniel Kulp ,  Joseph Jardine

IPC分类号： C07K14/005 ,  C12N7/00 ,  C12N9/10 ,  A61K39/21 ,  A01K67/027 ,  A61K49/00

CPC分类号： C07K14/005 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  A61K39/12 ,  A61K39/21 ,  A61K49/0008 ,  C07K2319/00 ,  C07K2319/21 ,  C12N7/00 ,  C12N9/1085 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12Y205/01078

摘要： The present invention relates to engineered outer domain (eOD) immunogens of HIV gp120 and mutants thereof and methods of making and using the same. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity. The mutant eODs bind to neutralizing antibody precursors. The mutant eODs can activate germline precursors on the pathway to eliciting a broadly neutralizing antibody (bnAb) response. The invention also relates to immunized knock-in mice expressing germline-reverted heavy chains. Induced antibodies showed characteristics of bnAbs and mutations that favored binding to near-native HIV-1 gp120 constructs. In contrast, native-like immunogens failed to activate precursors. The invention also relates to rational epitope design that can prime rare B cell precursors for affinity maturation to desired targets.